XFOR - 140% UPSIDE- Triangle breakout
- buy pullbacks dips
- Tipranks Analyst rating $22 median price target
- The FDA has designated Rare Pediatric Disease status to X4 Pharmaceuticals (XFOR -2.4%) for its lead asset, mavorixafor, for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis), a rare inherited, immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene (Vandana Singh, SA)
